Achieved 15.38% Growth: Korea’s ‌First Allergy Medicine with‌ Minimal Drowsiness Side Effect

allergy medicine with minimal drowsiness⁢ side effect’ (Fexofenadine soft‍ capsule)” width=”100%” height=”auto” loading=”lazy” decoding=”async” />

Alpibio announced on the⁣ 23rd that its domestically developed ‘allergy medicine with minimal drowsiness side effect’ had ‌surpassed 28 million units in cumulative production in just 6 months since its launch.

The ⁣recently launched general⁤ medicine ‘Fexofenadine soft capsule allergy medicine’ has ⁢officially surpassed 28 million units (in capsule units) in cumulative production in just 6 months‍ since its domestic launch.

The production volume of this ‍product has increased rapidly from 13​ million units last year to 15 million units this year,‌ achieving a 15.38% growth⁢ year-on-year.

Currently, Alpibio is in charge of ​development ​and manufacturing, and four pharmaceutical companies are in charge of sales. The official ​distributors of this product are SK Chemicals (in‍ partnership with Baropharm) ‘Nose Al⁣ Soft Capsule’, Green Cross ‘Allerjet‍ Soft Capsule’, JW Pharmaceutical ‘Algiquick Soft Capsule’, and Chong Kun Dang‌ ‘Cool Nose F Soft ‌Capsule’.

Fexofenadine is⁣ the antihistamine⁤ with ⁤the least drowsiness side effect, and can be safely taken during the day. Alpibio has developed a soft capsule formulation⁢ of the fexofenadine ingredient from the existing tablet through Alpibio’s ‘Fexofenadine solubilization patented method’, which was developed for the first time in Korea, thereby improving the absorption⁤ rate and bioavailability.

This product is expected to be especially useful for consumers who need ‌to avoid ‍drowsiness during the day, such as students who need⁣ to focus on their studies and transportation workers for whom drowsy driving can lead to fatal injuries.

Fexofenadine is the only⁤ second-generation antihistamine that has ⁢been proven to be effective in alleviating allergic symptoms caused ⁣by pollen and house dust⁢ (indoor dust), and is therefore considered suitable as a first-line drug for allergic symptoms⁤ caused by fine dust in spring ‌and ​fall.